ShangPharma considers going private amid compliance costs, share weakness
This article was originally published in Scrip
Executive Summary
The costs of compliance with disclosure and financial reporting obligations for public firms in the US, and a share price well below the initial public offering level, have apparently prompted another mid-sized Chinese operation in the pharma space to consider delisting.